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 Introduction 
IBD is a group of conditions which are idiopathic in origin producing chronic inflammation of 
the intestinal tract. Although IBD has been of considerable burden in the West, this entity is been 
increasingly diagnosed in Asian countries including India(1) This maybe due to increased 
awareness of the disease among physicians and improvements in the diagnostic modalities(1). 
Traditionally, mesalamine and steroid compounds have been used to manage IBD. More lately, 
immunomodulators and biological agents have been added to the therapeutic armamentarium.  
Opportunistic infections including viral infections are observed in those with IBD, one of which 
is hepatitis B infection(2)Chronic hepatitis B infection which affects more than 350 million 
worldwide can result in cirrhosis and hepatocellular carcinoma(4).India is generally considered 
as an area of intermediate prevalence(3).Although an effective vaccine exists, its coverage in 
India is suboptimal thereby increasing the risk of transmissibility of the virus to 
vulnerable(2).IBD patients are at risk for hepatitis B infection when they are subject to blood 
transfusions and surgical intervention(4).With increasing use of immunosuppressive therapy in 
IBD, reactivation of the hepatitis B virus is possible(4)(5)(6).At the same time, data even from 
the West also show that hepatitis B vaccination coverage in those with IBD is low(7)(8)(9). The 
seroprotection offered by the immunization with standard dose of hepatitis B vaccine is also 
suboptimal (9)(10)(11). 
Major guidelines on hepatitis B management strongly recommend testing for hepatitis B markers 
prior to initiating cytotoxic chemotherapy or highly immunosuppressive treatments(12)(13). 
ECCO guidelines advises treatment with for those positive for hepatitis B infection with anti 
viral  starting two weeks prior to onset of immunosuppressive therapy till up to 6 months of 
 cessation of the same. On the other hand vaccination is recommended for all those who are 
seronegative .Unfortunately, the awareness regarding vaccination and hepatitis B infection in 
IBD patients has been dismal among gastroenterologists (7). 
Data on the burden of hepatitis B infection in those with IBD is limited and the reported figures 
vary across studies (14)(15) . There has been no data in published literature from the Indian 
subcontinent with regard to this important issue and hence the need for embarking on this study. 
 
 
 
 
 
 
 
 
 
 
 
 
 AIM AND OBJECTIVES OF THE STUDY 
 
Aim: 
To study  the prevalence of hepatitis B infection in patients with inflammatory bowel disease. 
Objectives: 
1. To study the prevalence of serological markers of hepatitis B exposure in patients with 
inflammatory bowel disease. 
2. To study the hepatitis B vaccination status in patients with inflammatory bowel disease. 
 
 
 
 
 
 
 
 
 
 
 Review of literature: 
Inflammatory bowel disease (IBD) comprises of three major disorders: ulcerative colitis, Crohn's 
and indeterminate colitis.  
Ulcerative colitis: 
Inflammation of the mucosal layer of the colon characterizes ulcerative colitis. It usually 
involves rectum and extends to proximal parts of colon in continuity. 
Ulcerative colitis patients usually present with bloody diarrhea. As a result of rectal involvement 
stools are small and frequent in quantity. Colicky abdominal pain, urgency, tenesmus, and 
incontinence are associated symptoms. Patients who have distal involvement may have 
constipation as the only symptom. The severity ranges from mild disease with four or fewer 
stools with or without blood per day to severe disease with more than 10 stools per day (21). 
Fever, fatigue, and weight loss are also present. Symptoms secondary to anemia due to blood 
loss and anemia of chronic diseases include dyspnea and palpitation. The severity and presence 
of systemic symptoms depend on the clinical severity of the intestinal disease. 
Crohn's disease: 
 Transmural inflammation and skip lesions are the characteristic lesion seen in Crohn’s disease 
(CD).  The transmural inflammation may lead to fibrosis and strictures, and to obstructive 
clinical presentation. Transmural   inflammation may also results in sinus tracts, giving rise to 
fistulae and perforation. 
  Abdominal pain is a common symptom of CD irrespective of the disease distribution. 
Transmural inflammation causes fibrotic strictures. Repeated episodes of small bowel and 
colonic obstruction are caused by these strictures. Right lower quadrant pain is frequently present 
in patients with disease limited to distal ileum. Patients will have no clinical manifestations of 
CD sometimes until luminal compromise causes constipation and signs of obstruction and 
abdominal pain. Manifestations like diarrhea, fistulas, malabsorption and bleeding, 
intraabdominal abscess are also seen in Crohn’s disease. Extra intestinal manifestations like 
arthritis, uveitis, sacroileitis and skin manifestation like erythema nodosum, pyoderma 
gangranosum which may or may not be associated with disease activity are seen in both 
ulcerative colitis and CD. 
Indeterminate colitis: 
Surgical pathologists used  the term “indeterminate colitis” for cases of severe colitis in which 
the resected colon  showed features of both ulcerative colitis and Crohn’s disease(16). The use of 
the term “indeterminate colitis” has  widened to include colonoscopy and upper gastrointestinal 
(GI) endoscopic appearances,  findings of video capsule endoscopy, biopsies, serology and 
radiology with each modality showing diagnostic features of both ulcerative colitis and Crohn's 
disease(17)(18). Indeterminate colitis is used in cases in which infectious causes are excluded 
and  colonoscopy and upper GI endoscopy with biopsies,  small bowel follow through or 
enteroclysis are not conclusive for Crohn's disease or ulcerative colitis(19). Postresection 
indeterminate colitis  do have ulcerative colitis or Crohn's disease which was not diagnosed 
preoperatively(20).Indeterminate  has been termed as temporary diagnosis  as there is evolution 
to ulcerative colitis or Crohn's disease in some patients. Based on clinical, endoscopic and 
radiological features indeterminate colitis  appears to be a distinct a subgroup among pediatric 
 patients(21)Few patients of indeterminate colitis have a phenotype of inflammatory bowel 
disease  different from Crohn's disease and ulcerative colitis depends upon the identification of  
serological or genetic markers instead  of the exclusionary criteria . At present indeterminate 
colitis remains a diagnosis of exclusion. Medical treatment trials of indeterminate colitis which 
are prospective are not reported. Until there is a generally accepted positive diagnostic test to use 
as an inclusion criterion a prospective randomized trial for medical treatment is unlikely. Few 
studies has shown benefit of Infliximab in medical refractory indeterminate colitis 
patients(22).Ileal-pouch anal anastomosis  appears controversial in  patients of indeterminate 
colitis with few medical centers showing similar  results as in ulcerative colitis and few  showing 
less favorable outcomes(23) (31). Since ulcerative colitis and Crohn's colitis both has an 
increased risk of colonic malignancy, it also appears that patients with prolonged course of 
indeterminate colitis may also have increased risk for colonic malignancy 
 
Epidemiology: 
The incidence of inflammatory bowel disease (IBD) changes accordingly  as geographic location 
and ethnicity changes(24) .The areas with highest incidence are North America, England, North 
Europe and Australia. The incidence of IBD has been shown to be lower in southern compared 
with northern latitudes. In European countries  and North America, incidence rates  is 2.2 to 19.2 
for ulcerative colitis and 3.1 to 20.2for Crohn’s disease(25)(26)(27). The incidence and 
prevalence of ulcerative colitis  and Crohn’s disease seems to be lower in Asia and the Middle 
East(28). Seasonal variation in flares of IBD with peaks in the spring have been noticed(29) . 
 
  
Temporal influence 
IBD incidence may have changed over time. During the first several decades of the 
20thcentury,the incidence of Crohn’s disease was less than ulcerative colitis in America and 
northern Europe. The incidence of ulcerative colitis remained stable from the 1950s through the 
1980s while an increase in incidence of Crohn’s disease was persistently observed(30)(31). After 
that, the incidence of Crohn’s disease seems to have plateaued and  similar at present to 
ulcerative colitis in Europe  and North America (32).The prevalence of ulcerative colitis  has 
been reported to be substantially lower than among Europeans(33). 
Ulcerative colitis can present at all ages .The diagnosis of ulcerative colitis below 5 years and 
above 75 years is not common. The peak incidence of ulcerative colitis occurs in 2nd and 3 rd 
decades of life and 2nd peak between 60-70 years. No gender difference is seen at all ages. 
Crohn’s disease is common in people in their 20s and teens, and also in people in their 50s 
through to their 70s. In childhood it is rarely diagnosed. Females children are affected more 
severely than male (34).   Males are less likely to develop Crohn’s disease than females. There is  
increased risk to develop disease in parents, siblings and children of Crohn’s disease 
patients(35). 
Risk factors for inflammatory bowel disease: 
Age and gender: The age of onset is usually around 15 and 40 years. There is a bimodal age 
distribution for ulcerative colitis as well Crohn’s disease with  second  peak seen between 50 to  
80 years(36). 
 Racial and ethnicity :Ulcerative colitis and Crohn’s disease are more common in Jews than 
non-Jews(37).Whites are affected more commonly than black and Hispanic populations (38). 
Genetic susceptibility :10 to 25% IBD patients have a first degree relative with Crohn’s 
disease or ulcerative colitis (39)(40).There appears to be concordance for the same disease type 
within families as with Crohn’s disease(41). 
Smoking: It has a variable effect on ulcerative colitis and Crohn’s disease. Nicotine and 
smoking  may directly smooth muscle tone, gut permeability, affect mucosal immune responses 
and microvasculature(42)(43)(44)(45). 
Diet: Food antigens probably incite an immunologic response which results in IBD.Particular 
pathogenic antigens have not been identified yet. A diet with fried food, sugary foods, and 
processed food is associated with an increased risk of developing Crohn’s disease and possibly 
ulcerative colitis. Cow's milk protein hypersensitivity has also been shown in infancy to cause of 
IBD(46). Sugar which is refined has been linked to the development of IBD(47)(48).Dietary 
fiber,  from fruit, has been associated with a decrease in risk of Crohn’s disease.(49)(50). 
Physical activity :Physical activity has been associated with a decrease in risk of Crohn’s 
disease(51). 
Obesity :It is not clear whether obesity is associated with an increased risk IBD 
(52)(53).Accumulation of abdominal fat may lead to mucosal inflammation thereby altering the 
clinical course  of established IBD(54). 
 Infections : Gut microbiome imbalance may lead to the development of IBD. The role of 
infections is suggested by the correlation between specific microorganisms and IBD and the 
association between acute gastroenteritis and IBD(55). 
Nursing and other perinatal events: Breast feeding and perinatal events such as 
infections are  implicated as a risk factors for IBD although the association is not clear(56)(57). 
Antibiotics: Antibiotics, by altering the gut flora, may be a risk factor for IBD. Antibiotic use 
appears to have causal association(58)(59). 
Oral contraceptives and hormone replacement therapy: Oral contraceptive and 
hormone replacement therapy through thrombotic effects may predispose to IBD. However the 
risk is small(60)(61). 
Nonsteroidal anti-inflammatory drugs: NSAIDS can affect the interaction between 
immune cells in the intestine and the gut microbiome. They can also alter platelet aggregation, 
the release of inflammatory mediators, and micro vascular response to stress which are key 
events in the pathogenesis of IBD(62)(63). 
Appendectomy: Appears protective for  development of ulcerative colitis but the mechanism 
of is unknown(64)(65). 
Psychosocial factors : The association  is controversial and inconsistent(66)(67). 
 
 
 Etiology and pathogenesis: 
The etiology of inflammatory bowel disease is multifactorial.It involves interaction of three 
elements. 
1) Genetic susceptibility 
2) Host immunity 
3) Environmental factors 
Genetics: 
Genetics factors are risk factors for development of inflammatory bowel disease. Family history 
of IBD is one of the strongest risk factors. Animal and human studies have proved the 
association. IBD follows a non-Mendelian pattern of inheritance. Twin studies give the most 
compelling clinical evidence which  suggest that genetic factors are  more important in CD than 
in UC(68)(69). First-degree relatives have 3 to 20 times more risk to develop the disease than the 
general population (69). Sibling are diagnosed within ten  years (70). Children of Jewish patients 
may be at a higher risk of developing IBD(71). Clinical features also demonstrate a heritable 
pattern. Concordance in the location (eg, ileal versus colonic) and type (eg, fibrostenotic, 
fistulas) of CD has been observed(72)(68).Genetic anticipation has also been described in 
inflammatory bowel disease(73)(74).It is been shown that the aggregate effect at several loci 
contributes to the IBD phenotype(75)(76). A genome-wide association studies (GWAS), have 
implicated 100 distinct susceptibility loci for IBD(77)(78)(79). 
 Intracellular innate immune pathways recognizing microbial products in the 
cytoplasm: The IBD1 gene on chromosome 16 encodes the protein NOD2 (CARD15). 
Mutations in IBD1 confer susceptibility to ileal CD(74)(80)(81). 
The autophagy pathway : CD genes (ATG16L1, IRGM, and LRRK) regulate the 
autophagy pathway which is homeostatic process that enables recycling of intracellular 
organelles and contributes to the removal of intracellular microorganisms(79)(82). Some studies 
suggest NOD2 pathway regulate autophagy, integrated and defective in some patients with 
CD(83)(84). 
Pathways regulating adaptive immunity: Genes regulating IL-17 and IL-23 receptor 
pathway have proposed as risk for IBD risk (eg, IL23R, IL12B, and STAT3).  (STAT3, JAK2, 
and TYK2)genes overlap with the IL-10 pathway that has  been associated with UC and CD(85). 
Major histocompatibility complex:  IBD with major histocompatibility complex (MHC) 
loci association has been proven multiple studies. HLA-DR2 is associated with UC, particularly 
in Japanese patients. Patients with HLA-A2, HLA-DR1, and DQw5 have increased risk of 
Extraintestinal manifestations of CD. In a GWAS of a Japanese population, HLA-Cw*1202-
B*5201-DRB1*1502 haplotype is associated with increased chance of developing UC but 
decreased risk for CD(86). 
 
 
 
 CLINICAL MANIFESTATION OF ULVCERATIVE COLITIS: 
Colitis: Ulcerative colitis patients present with chronic bloody diarrhea. It is usually a large 
bowel type diarrhea. Abdominal pain, urgency, tenesmus, and incontinence are usually 
associated.Patienst with distal disease can present with constipation. The onset of symptoms is 
usually insidious. The severity is from mild disease with four or fewer stools per day with or 
without blood  and severe disease with more than 10 stools per day with continuous bleeding and 
severe cramps (87).Systemic symptoms including fever, fatigue, and weight loss are also 
reported. Symptoms of anemia are also noted. Physical examination is usually normal, especially 
in mild disease. Moderate and severe ulcerative colitis may have abdominal tenderness to, fever, 
pallor, hypotension and tachycardia. On rectal examination there may be blood.  Physical 
examination may show muscle wasting, loss of subcutaneous fat, and peripheral edema due to 
malnutrition.         
Disease severity: the severity is important for clinical management and assessing the long 
term prognosis. It is measured using a clinical disease activity index(88). 
Mild: Patients have four or fewer stools per day which may or may not have blood without 
signs of systemic toxicity, and a normal ESR.  
Moderate: Patients have frequent loose, bloody stools (>4 per day), mild anemia which does 
not require blood transfusions, and non-severe pain and minimal signs of systemic toxicity. 
 
 Severe – It is usually associated with frequent loos stools (≥6 per day) with blood and signs of 
systemic toxicity such as tachycardia (heart rate ≥90 beats/minute), fever (temperature ≥37.5ºC), 
anemia (hemoglobin <10.5 g/dL), and ESR (≥30 mm/hour). 
Most of the ulcerative colitis patients present with mild disease , 27 percent of patients present 
with moderate disease, and 1 percent present with severe disease(89). The Mayo scoring system 
is used to assess disease severity and monitoring. Scores range from 0 to 12 with higher scores 
predicting severity(90). 
 
Diagnosis: It is based on the history of diarrhea which persist  more than four weeks and 
endoscopic and histologic features. Endoscopic and histological features are not specific for 
ulcerative colitis, so for confirming the diagnosis requires the exclusion of other causes of colitis. 
 
LABORATORY FINDINGS: Patients with severe disease may have high ESR, electrolyte 
abnormality, low albumin and anemia. Patients with primary sclerosing cholangitis have raised 
alkaline phosphates. Stool studies include routine stool cultures and stool Clostridium difficile 
toxin, Giardia stool antigen and microscopy for ova and parasites .Serologic testing for sexually 
transmitted diseases including should be considered, particularly in patients with rectal 
symptoms. 
Endoscopy and biopsy: In patients with ulcerative colitis endoscopic findings are 
nonspecific. The endoscopic features include erythematous appearance and loss of vascular 
markings due to engorgement of the mucosa and granularity of the mucosa, petechiae, exudates, 
 edema, erosions, touch friability, and spontaneous bleeding may present. Severe disease can be 
associated with ulcerations, profuse bleeding, and copious exudates. Pseudopolyps may be 
present. 
Biopsy features suggestive of ulcerative colitis include architectural distortion such crypt 
abscesses, crypt branching, shortening and disarray. Epithelial changes such as mucin depletion 
and Paneth cell metaplasia may be seen. None of these features are specific for ulcerative colitis, 
the presence of two or more histologic features is  suggestive of ulcerative colitis(91)(92).  
In ulcerative colitis, rectum is usually involved initially which extends proximally in a 
continuous manner. In 30 to 50 percent of patients, disease is limited to rectum and sigmoid 
colon, 20 to 30 percent have left-sided colitis, and 20 percent of patients have pancolitis. Some 
patients have focal inflammation around the appendiceal not in continuity with disease elsewhere 
in the colon (a "cecal patch")(93)(94). Ileal inflammation (“backwash” ileitis) may occasionally 
be seen in patients with ulcerative colitis. 
IMAGING: 
Abdominal imaging is usually normal in mild to moderate disease patient, but may detect 
mucosal thickening or “thumb printing” due to edema. It can also detect colonic dilation in 
patients with severe ulcerative colitis. 
Double contrast barium enema can be normal in mild disease. Barium enema shows diffusely 
reticulated pattern with punctuate collections of barium. In severe disease, it shows spiculated 
collar button ulcers, loss of haustrae, shortening of the colon, pseudo polyps, and filiform polyps 
and narrowing of the luminal caliber. 
 Ultrasound may show thickened hypoechoic mucosal layer in patients with active disease. 
Severe cases ma show transmural bowel wall thickening. Sonographic findings are non-specific 
for U.C and may be seen colitis due to other causes. 
Computed tomography (CT) and magnetic resonance imaging (MRI) demonstrate thickening of 
the bowel wall which is nonspecific.  
Clinical features of Crohn’s disease: 
Fever, abdominal pain, diarrhea with or without bleeding and weight loss are predominant 
symptoms of CD (95). Physical examination may be normal or may show pallor, weight loss.  
Other specific findings include perianal skin tags, sinus tracts, and abdominal tenderness. 
Abdominal pain: Abdominal pain is a commonest feature .Transmural involvement  causes 
fibrotic strictures leading to repeated episodes of small bowel and colonic obstruction. Patient 
whose disease is limited to the distal ileum may presents with pain right lower quadrant. 
Diarrhea: Diarrhea is a common presentation.  A history of chronic diarrhea without bleeding 
but with extra intestinal manifestations of (IBD) (eg, skin, eye, or joint problems) suggests the 
diagnosis of CD. Diarrhea associated with CD may result from secretion of excessive fluid and 
impaired fluid absorption by inflamed small or large bowel, malabsorption of bile salt and 
steatorrhea. 
Bleeding: There may occult gastrointestinal blood loss and overt bleeding is less common 
however patients with Crohn’s colitis can have overt bleeding. 
 Fistulas -Transmural inflammation is associated with the development of fistulas. It is  usually 
an indolent process. Fistulas connect two epithelial-lined organs. Common types for fistulas are 
enterovesical, enterocutaneous, enteroenteric and enterovaginal. 
Phlegmon/abscess: Sinus tract do not from fistulas every time. They may present as a 
phlegmon which may be palpable on physical examination. Mass in the right lower quadrant 
may suggest ileal involvement. Abscess may form in sinus tracts which lead to localized 
peritonitis with fever, abdominal pain and tenderness 
Perianal disease: Perianal disease may occur in more than third of patients with CD and may 
cause symptoms like perianal pain and discharge from large skin tags, perirectal abscesses, anal 
fissures and anorectal fistulas. 
Malabsorption: Occurs due to bile salt diarrhea as the terminal ileum is commonly involved. 
Steatorrhea may also result from bacterial overgrowth from enterocolonic fistulas, small bowel 
stricture or extensive disease. Steatorrhea can lead to severe malnutrition and manifestation of fat 
soluble vitamin deficiency. 
Other gastrointestinal involvement.: There may be frequent apthous oral ulcers 
.Esophageal CD can present as  dysphagia.Gastroduodenal CD can be seen in 15 percent of 
patients, may present as of gastric outlet obstruction or upper abdominal pain (96). Gallstones are 
also seen commonly (97). 
 
 
 Extraintestinal manifestation of inflammatory bowel disease: 
IBD is associated with multiple extraintestinal manifesations. Ten percent of patients with IBD  
usually develop extraintestinal manifestations initially. However 25 percent of patients develop 
extraintestinal manifestations in the course of the disease(98). EIM usually follow the clinical 
course of IBD except primary sclerosing cholangitis and ankylosing spondylitis. 
Musculoskeletal: The most common extraintestinal manifestation of IBD is arthritis. IBD is 
associated with peripheral arthritis which usually involves large and small joints and ankylosing 
spondylitis. Osteopenia, osteoporosis and osteonecrosis are other manifestations of IBD. 
 Arthritis can affects appendicular joints, the spine, sacroiliac joints or a combination of these  
joints. Peripheral arthritis can be remitting and acute in onset when it is called Type I arthropathy 
or  it can be chronic and have frequent relapses when it is called type 2 arthropathy(99).IBD 
complications can cause joint pain  that should be distinguished from sterile inflammation. 
Bacterial infection of the peripheral and sacroiliac joint can occur due to fistulization and 
bacteremia. Joints can also be affected due to adverse effects of IBD treatment. Osteonecrosis 
due to glucocorticoids use is common. 
Spondylitis can occur up to 26 percent IBD  patients (100)(101) Females are less commonly 
affected than males. Prolonged stiffness in the back in the morning or after rest is the usual 
symptom. Exercise relives pain and stiffness usually. Symptoms are not related to the 
gastrointestinal disease. Asymptomatic sacroileitis by radiological detection is seen up to 18 
percent of patients with IBD(102).There is no increased frequency of HLA-B27 in  patients with 
IBD and sacroileitis. 
 Type I arthropathy — It is acute, affects six or fewer joints and is associated with flares of 
the bowel disease usually in initial stages of the disease. It is self-limiting and does not cause 
joint deformities. The knee is most commonly affected. Five percent of IBD patients develop 
type I arthropathy. Joint symptoms can arise prior to the onset IBD. 
Type II arthropathy — It is a polyarticular disease with metatarsophalangeal joints being 
commonly involved (99). Other joints like proximal interphalangeal, metatarsophalangeal joints, 
ankles, knees, shoulders elbows and wrists joint are infrequently involved. Approximately one-
half of the patients with IBD have migratory arthritis. Synovitis which is active can remain for 
months and can relapse multiple times. Exacerbations and remissions of the symptoms can 
persist for years. It affects up to 4 percent of IBD patients.  Joint involvement infrequently can 
occur before the diagnosis of IBD and joint symptoms do not follow the activity of bowel 
disease(99). 
Skin: 
Erythema nodosum —  This  skin disorder is frequently seen with ulcerative colitis and 
Crohn’s disease and can occur in 4 percent of patients(103). It occurs as raised, tender, red 
subcutaneous nodules. The size can vary from 1 to 5 cm. Extensor surfaces of the extremities  
are the usual location of the nodules specifically over the anterior tibial area. Biopsy from these 
lesions shows focal panniculitis. The diagnosis is most often clinical and biopsy is rarely 
required. 
 
 Pyoderma gangranosum  — Very few patients  of inflammatory bowel disease develop 
pyoderma gangranosum (104) . It usually affects only 0.75 percent of patients (103).It is 
relatively infrequent, however it has more serious consequences than other skin disease 
associated with IBD such as persistence and local discomfort even after appropriate therapy. 
It usually occurs as single or multiple erythematous papules or pustules. It shows pathergy as 
lesions which are usually preceded by trauma to the skin. The most common locations are the 
legs, but it may develop in  other parts of the body such the abdominal wall adjacent to the stoma 
after colostomy as well as in areas of trauma or other surgical scars (105). Deep ulcerations 
develop due to necrosis of dermis which is sterile on culture. Biopsy reveals findings such as 
sterile abscess. 
Pyoderma gangranosum parallel IBD activity in half of the cases(106). Therapy of underlying 
IBD results in healing although treatment often includes a long course of high dose 
glucocorticoids. 
Eye – Common ocular manifestations of IBD include episcleritis and uveitis, scleritis, iritis , 
and conjunctivitis. It can be asymptomatic or   patients may complain of burning, itching or 
redness of the eyes. 
Episcleritis/Scleritis It occurs in  up to 5 percent of patients with IBD(107).Patients may be 
asymptomatic or complain of itching and burning ciliary vessels injection and inflammation 
episcleral tissues are important features on examination.Episcleral nodules can also be seen. 
 Uveitis — This is less common than other eye conditions associated with IBD and occurs up to 
3 percent of patients with IBD. The consequences are more severe with uveitis.  It is bilateral, 
insidious in onset ,posterior to the lens, chronic and  is more common in females than 
males(108). It is usually associated with arthritis in 75 percent of patients which may be axial 
and/or peripheral and therefore seems like spondyloarthropathy. It may be difficult to 
differentiate between these disorders as half of patients with IBD have the HLA-B27 phenotype 
.(109)The common symptoms are blurred vision, eye pain, photophobia, and headaches. A slit-
lamp examination shows inflammation in anterior chamber with per limbic edema, cells, and 
protein. Conjunctival injection and corneal clouding can also be seen. Iris atrophy, lens deposits, 
and synechiae can develop after an acute episode. 
Hepatobiliary: Primary sclerosing cholangitis and autoimmune liver disease are usually 
associated with IBD. Primary sclerosing cholangitis patients are usually asymptomatic and are 
suspected due to elevation in the alkaline phosphates concentration. Common symptoms are 
right upper quadrant pain, fevers, fatigue, pruritus, chills and night sweats. 
Hematopoietic: IBD  patients are at an increased risk for  venous and arterial thromboembolic 
events.(110)(111) 
 
 
 
 
  
Diagnosis: 
Laboratory findings: There may be anemia, vitamin B12 deficiency and raised 
inflammatory markers such as ESR and CRP. In cases of diarrhea, a stool specimen should be 
examined for culture, ova and parasites and C. difficile toxin. 
 
Endoscopy: 
Colonoscopy — Colonoscopy with ileal inspection is the modality of choice for diagnosis. 
Endoscopy shows ulcerations near the normal appearing mucosa with polyploidy mucosal 
changes which give rise to cobblestone appearance. CD involvement is typically focal with 
normal appearing bowel segments in-between. Pseudopolyps are also often present. Rectal 
sparing is common in Crohn’s disease. Biopsies are obtained from the right colon, left colon, and 
rectum even if endoscopically normal in appearance to assess for microscopic inflammation. 
The major findings on intestinal biopsy are focal ulcerations, acute and chronic inflammation. 
These findings are usually confirmatory rather than diagnostic. Granulomas are seen up to 30 
percent of CD   patients and are diagnostic. 
Wireless capsule endoscopy — Wireless capsule endoscopy is being used frequently for 
the evaluation of suspected and established small bowel Crohn disease. It provides another way 
 of small bowel visualization. It can detect lesions which are suggestive of CD but not visible by 
other studies. 
Imaging studies — They are useful to evaluate the upper gastrointestinal tract and for 
detection of the length and location of strictures in areas not accessible by colonoscopy. Imaging 
studies includes barium studies, such as barium enema or upper gastrointestinal series with small 
bowel follow through (SBFT), computed tomography (CT) and magnetic resonance (MR) 
enterography in patients with Crohn disease. 
 
Medical management of ulcerative colitis: 
Management depends upon disease location and severity. 
Ulcerative proctitis or proctosigmoiditis: 
 Topical 5-aminosalicylic acid (5-ASA) medications are first-line treatment. 5-ASA 
suppositories and enemas induce remission in more than 90 percent of patients with mild to 
moderate proctitis(112)(113). Topical therapies are quicker  to act than oral preparations and 
require less  dosing(114).Patients reluctant or who are unable to tolerate topical medications are 
treated with oral 5-ASA medications. Oral therapy alone is effective in the induction of 
remission in patients with proctitis and proctosigmoiditis in but response rate is lower than 
topical therapy (115).Patients who do not have  response  adequately to topical therapy are 
usually treated with the combination of oral 5-ASA and topical 5-ASA enemas or 
 suppositories(115). For patients who do not respond to topical 5-ASA medications  in four to six 
weeks, a combination of topical 5-ASA and topical steroids should be used(116). 
 
Maintenance therapy: For patients with first episode of mild ulcerative proctitis who have 
responded to treatment, maintenance therapy is not recommended. Many such patients continue 
to be in remission for long periods without having a relapse and even if it occurs, the response to 
therapy is often prompt and complete. Patients with ulcerative proctitis who have more than one 
relapse in a year and in all patients with proctosigmoiditis, maintenance therapy is recommended  
(117). 
Left-sided colitis, extensive colitis and pancolitis: 
Combination therapy with oral 5-ASA medications, 5-ASA or steroid suppositories, and 5-ASA 
or steroid enemas or foam are beneficial in patients with mildly or moderately active left-sided 
colitis and pancolitis(118). Oral glucocorticoids are  effective in inducing remission in patients 
with active ulcerative colitis in patients non-responsive to 5-ASA and tropical therapy(119). 
Maintenance therapy:  In all patients with left-sided colitis, pancolitis, or extensive 
colitis; maintenance therapy is recommended. 
Steroid refractory ulcerative colitis: Patients without clinical response to glucocorticoids 
in doses of prednisone upto 40 to 60 mg/day within 30 days for oral therapy or 7 to 10 days for 
intravenous therapy are considered to have steroid-refractory disease. Medical therapy with 
cyclosporine as a   "bridge" to therapy with longer acting medications azathiporine and 
 Mercptopurine and an anti-tumor necrosis factor (anti-TNF) agent, additional are considered for 
patients with steroid-refractory ulcerative colitis. 
 
Steroid dependant ulcerative colitis: 
Steroid dependence is defined as where glucocorticoids cannot be tapered to less than 10 mg/day 
within three months of starting steroids without recurrent disease, or where relapse occurs within 
three months of stopping glucocorticoids. Longer acting medications like Azathioprine and 
Mercptopurine and Anti-TNF agents are options for steroid dependant patients. 
Medical management of Crohn’s disease: 
Usually disease severity dictates management. The Crohn's Disease Activity Index (CDAI) and 
similar scoring systems are used to assess the disease activity in crohn’s disease(120). The latter 
have been shown to correlate with the CDAI(121). A drop in the CDAI of 100 points 
corresponds to a 3-point drop in the HBI. A CDAI of <150 (clinical remission) corresponds to 
Harvey-Bradshaw Index of <4. 
Disease severity according to CDAI is defined as follows 
Asymptomatic remission (CDAI <150): Defined as patients who have remission either 
spontaneously or after medical or surgical therapy. Patients who require steroids to remain 
asymptomatic are not in remission and are labeled as steroid-dependent. 
 Mild to moderate Crohn disease (CDAI 150-220) – Refers to patients who are 
tolerating an oral diet without dehydration, mass, obstruction, toxicity, abdominal tenderness or 
>10 percent weight loss. 
Moderate to severe Crohn disease (CDAI 220-450) – Patients who did not respond to  
management for mild to moderate disease and patients with  weight loss, fever, nausea ,vomiting, 
abdominal pain and tenderness or anemia. 
Severe-fulminant disease (CDAI >450):Persisting symptoms such as high fevers, 
intestinal obstruction, persistent vomiting, cachexia, significant peritoneal signs or an abscess 
despite glucocorticoids or biologic agents (Infliximab, adalimumab, certolizumab pegol or 
natalizumab). 
Drugs used in management of mild to moderately severe Crohn’s disease: 
5-ASA drugs — There is controversy regarding the use of 5-ASA drugs for Crohn’s disease. 
Studies have produced mixed results evaluating the efficacy of 5-ASA drugs in Crohn’s disease. 
Meta-analysis have shown that Mesalamine is not superior to placebo in induction and 
maintenance of remissions but some studies have shown that Sulfaslazine is superior to placebo 
but inferior to steroids in inducing remission.  Higher dose of mesalamine (1.5gm/day) is also 
shown to induce remission in Crohn’s disease(122). 
Glucocorticoids — For mild to moderate disease, oral glucocorticoids continue to be the 
mainstay of treatment and for those presenting with more severe  symptoms but not requiring 
intravenous glucocorticoids and hospitalization (123)(124)(125). Antibiotics and 5-ASA drugs 
 can be used concomitantly with prednisone. Because of significant side effects, glucocorticoids 
should not be used long-term. 
Non-systemic glucocorticoids — For the induction of remission in active ileitis or right-
sided colitis among patients who did not tolerate or who have contraindications to systemic 
glucocorticoids. Controlled ileal release budesonide which has high first-pass hepatic 
metabolism can be used as a prednisone alternative. Systemic side effects are less common with 
budesonide than with conventional glucocorticoids. It cannot be used for maintenance of 
remission although budesonide is recommended as first-line therapy for mildly to moderately 
active Crohn’s disease(116). 
Antibiotics: In septic complication of IBD such as wound infections and abscesses, antibiotics 
have very effective role in the treatment.  Although they are not an established   treatment of the 
primary disease processes of Crohn's disease, ulcerative colitis, they are still used 
commonly(126)(127)(128).Antibiotics may also act as immunomodulators and  exert their 
beneficial effects apart from antimicrobial effects(129)(130).  
 
Drugs used in management of severe and refractory disease: 
Azathioprine and 6-mercaptopurine: Azathioprine and its active metabolite, 6-
mercaptopurine are used in patients with refractory Crohn’s disease. The response rate is 60 to 
70 percent in both small bowel and colonic disease. Three to six months are required to notice 
 response to these medications. Patients usually require concomitant steroid therapy with a 
tapered steroid dose after one to two months of treatment with these agents. 
 
Methotrexate —For patients who show intolerance or do not respond to Azathioprine or 6-
MP; methotrexate is an alternative and may be preferable to Azathioprine or 6-MP in patients 
with arthropathy associated with CD. A response is usually seen within three months. 
Biologic therapies: 
Anti-TNF therapies — Three anti-tumor necrosis factor therapies are approved for treatment 
of luminal Crohn’s disease in adults and they all are effective. Patients who are unlikely to 
benefit are those with fibrostenotic Crohn’s disease without active inflammation. Patients who 
are intolerant to one anti-TNF agent may tolerate a different agent. In moderately active, steroid 
refractory Crohn disease, Infliximab has been shown to be useful for induction of remission after 
initial infusion and for maintenance of remission for up to 54 weeks. Its use has been associated 
with reduction in the risk of hospitalization and surgery  along with  improved quality of 
life(131). 
 
 
 
 
 Hepatitis B: 
Even after the availability of an effective vaccine for Hepatitis B virus, infection remains a 
global health issue. In the world, there are up to two billion individuals with evidence of hepatitis 
B infection. Of these, 400 million are chronic carriers and 500,000 to 1.2 million will succumb 
very year to cirrhosis and hepatocellular carcinoma. 
Epidemiology— In areas with low prevalence like United States and Canada, Western 
Europe, Australia;  the prevalence of HBV carriers varies from 0.1 to 2 %. In intermediate 
prevalence areas  like Mediterranean countries, Japan, Central Asia, Middle East, and South 
America; it is around 3 to 5 percent while in  areas with high prevalence like southeast Asia, 
China, sub-Saharan Africa; the prevalence  is  around 10 to 20 percent (132)(133).The variation 
in HBV carrier rate in different geographical regions of the world is because of differences in the 
age of acquisition of  infection. For vertically transmitted infection; the rate of progression  to 
chronic HBV infection is around 90 percent (134), between the age of 1 and 5 years the risk is 20 
to 50 percent (135) and for adult acquired infection, the risk is less than 5 percent. In India, the 
estimated  hepatitis B virus carrier rate in India is 4% with a total of around 36 million 
carriers(136). 
Mode of transmission: The mode of transmission varies according to the geographical area. 
In high prevalence areas, vertical transmission causing perinatal infection is the most common 
mode of transmission (133)(137). In intermediate prevalence areas, horizontal transmission in 
childhood, accounts for most common cause of chronic HBV infection. Intravenous drug use and 
 unprotected sexual intercourse are the major routes of transmission in low prevalence areas in 
adults. 
Screening for hepatitis B virus is performed by testing for HBsAg. Negative patients should be 
vaccinated. 
The following groups should be screened for HBV infection(12). 
1. Adolescents, who engage in high-risk behaviors like unprotected sex with an infected 
partner or more than one partner, use of  intravenous or intranasal drugs, those with a 
history of sexually transmitted disease and men having sex with men. 
2. All internationally adopted children. 
3. Immigrants from high prevalence areas (regions in which the HBsAg prevalence is more 
than 2 percent).  
4. Children who are living in communities where HBV is endemic. 
5. Household contacts of individuals with HBV infection. 
6. Infants born to women with HBV infection. 
Clinical manifestation: 
Acute HBV infection: The diagnosis is established in those who are positive for HBsAg 
IgM anti-HBc. One to four months is the incubation usually. A serum sickness-like syndrome 
usually develops in the prodromal period which is followed by constitutional symptoms such 
as right-upper-quadrant discomfort, jaundice, anorexia and nausea. After one to three months 
the symptoms and jaundice generally disappear. Subclinical or anicteric hepatitis develops in 
 around 70 percent of patients with acute hepatitis B and another 30 percent develop icteric 
hepatitis. The disease is usually more severe in patients who have confection with other 
hepatic viruses(138). In approximately 0.1 to 0.5 percent of patients, fulminant hepatic 
failure develops which is unusual(139).The age at infection decides rate of progression from 
acute to chronic hepatitis B (134). The rate is around 90 percent for vertically acquired 
infection. For infections between the age of one and five years, the rate is 20 to 50 percent  
and less than 5 percent for an adult-acquired infection(135) (137). 
Treatment: Acute hepatitis B treatment is supportive. Exposed contacts should be 
prevented from infection with appropriate measures. The role of nucleoside/tide therapy is 
not clear at present. 
Chronic HBV infection: HBsAg persistence for more than 6 months satisfies the criteria 
for chronicity. In chronic infection IgG anti-HBc is positive, while IgM anti-HBc is negative. 
Most of the patients are asymptomatic while some patients may have fatigue. Exacerbations 
of the infection which may be asymptomatic can mimic as acute hepatitis or manifest as 
hepatic failure. 
Chronic Hepatitis B infection can have different phases. The interplay between virus 
multiplication and the immune response of the host decides the natural course of chronic 
hepatitis B virus infection. There are two phases of chronic HBV infection usually: an early 
replicative phase with active liver disease and a phase with low replication and remission of 
liver disease(140)(141).  In vertically acquired HBV infection, virus replication is not 
accompanied by active liver disease. This is called as immune tolerance phase(142). 
 Replicative phase: 
 Immune tolerance — In vertically acquired HBV infection, the early phase is 
characterized by high HBV replication. There is the presence of HBeAg  and high levels of 
HBV DNA in serum, however there is no evidence of  liver disease as there are no 
symptoms, normal serum liver enzymes concentrations and minimal changes on liver 
biopsy(143)(144). 
Immune clearance: In the second and third decades in patients with vertically acquired 
HBV infection,  transition from the immune tolerance to the immune clearance phase occurs. 
The annual rate of spontaneous HBeAg clearance increases to 10 to 20 percent during the 
immune clearance phase(145)(146).HBeAg seroconversion is sometimes accompanied by 
biochemical exacerbations(147)(148). Most of the exacerbations develop without symptoms 
and usually identified during routine follow-up. In some  patients, symptoms of acute 
hepatitis develop and may erroneously lead to  diagnosis of acute hepatitis B (149). 
Low or nonreplication phase/inactive carrier state: Low or nonreplicating 
phase/inactive carrier state patients are those who are HBeAg negative and anti-HBe 
positive. Even when tested by PCR assays, HBV DNA is undetectable in serum in some 
patient. Liver disease is in remission as there is no evidence of necroinflammation in liver 
biopsies and normal liver function test. 
HBeAg-negative chronic hepatitis : Some patients remain HBeAg negative however 
they develop moderate levels of HBV replication and active liver disease (elevated liver 
function test and liver biopsy showing chronic inflammation)(150)(151). Such patients are 
 said to have HBeAg-negative chronic hepatitis. Due to precore or core promoter genetic 
variations, they cannot produce HBeAg and have a residual wild-type virus or HBV 
variants(152)(153).HBeAg-negative chronic hepatitis patients are older and they can have 
advanced liver disease and  have  fluctuations in HBV DNA and  liver enzymes. 
Resolution of chronic HBV infection: Patients with chronic HBV infection become 
HBsAg negative sometimes. The annual rate of clearance of HBsAg is usually around 0.5 to 
2% in Western countries and around 0.1 to 0.8% in Asian countries(154)(155).Clearance of 
HBsAg does not safeguard from the development of hepatocellular carcinoma or cirrhosis  
although they have a favorable prognosis(156). 
Sequelae of chronic Hepatitis B infection: Inactive carrier state to the development 
of cirrhosis, hepatocellular carcinoma, hepatic decompensation, extrahepatic manifestations 
and death are the usual sequel of hepatitis B infection. 
Chronic Liver Disease: Chronic Hepatitis B progresses to compensated and 
decompensated chronic liver disease at  different rates(157). 
• Chronic hepatitis to cirrhosis develops in around 12 to 20 % 
• Compensated cirrhosis to hepatic decompensation  develops in around 20 to 23 % 
•  Compensated cirrhosis to hepatocellular carcinoma develops in around 6 to 15 %. 
 
 
 Hepatocellular carcinoma : Seen in both Asian and Western populations. 
 Hepatocellular carcinoma (HCC)  is described in children and adults with HBV 
infection(158)(159). In perinatally acquired HBV infection, HCC develops at a rate of about 
5 percent per decade. The risk is related to the degree of histologic injury, the duration of 
disease, HBV DNA levels. HBeAg positive patients and  those with precore mutants have 
higher risk. 
 
Treatment of Hepatitis B: 
Treatment of chronic HBV is shown to decrease the risk transmission to others, progressive 
CLD and other long-term complication such as hepatocellular carcinoma. 
Patients can be categorized for treatment as follows:  (160) 
Patients in whom therapy is definitely indicated:  
- Clinical complications of chronic liver disease 
- Prevention of reactivation of chronic HBV during chemotherapy and immunosuppresion 
-  Cirrhosis and advanced fibrosis associated with high serum HBV DNA. 
   Therapy may be indicated in following group of patients: 
- Those with immune-active phase. 
     Immediate therapy is not routinely indicated in following groups of patients 
 - Immune tolerant phase. 
- Inactive carrier phase. 
-  Latent HBV infection (HBV DNA without HBsAg). 
Recommendations from the EASL suggest that patients with HBV DNA levels greater than 2000 
IU/mL, having serum ALT levels above the upper limit of normal (ULN) with evidence of 
moderate to severe necroinflammation and/or at least moderate fibrosis on liver biopsy should be 
treated(13). 
HBeAg-positive patients: 
 In patients with HBV DNA >20,000 IU/mL and ALT >2 x ULN; anti-viral therapy is 
recommended. Those having cirrhosis which is compensated and HBV DNA >2000 IU/mL and 
those with decompensated cirrhosis and detectable HBV DNA by PCR assay should be treated. 
Observation can be done in patients with chronic hepatitis with serum ALT less than two times 
the  normal but should be considered for treatment when the serum ALT becomes elevated. 
Patients who have icteric flares, recurrent hepatitis flares that fail to clear HBeAg, those with 
active or advanced histologic findings, and patients older than 40 who remain HBeAg positive 
and with high HBV DNA levels are exceptions. 
HBeAg-negative patients: 
 Treatment may be initiated when serum ALT is more than two times the normal and HBV DNA 
is more than 2000 IU/mL as sustained remission is rarity without treatment. Follow-up is 
required to differentiate an inactive carrier state from HBeAg negative chronic hepatitis because 
HBeAg negative chronic hepatitis has a fluctuating course. In HBeAg negative patients who 
 have serum HBV DNA levels >2000 IU/mL and normal or mildly elevated ALT, a liver biopsy 
should be considered to determine if therapy is required. 
 
Treatment: 
Therapy for chronic HBV includes Interferon, Lamivudine, Adefovir dipivoxil, Telbivudine, 
Entecavir and Tenofovir. 
Interferon: The advantages are the absence of selection of resistant mutants, finite duration of 
treatment and more durable response. Interferon side effects can be troublesome for some 
patients and severe side effects are less common. Interferon is contraindicated in patients with 
decompensated disease. The main role of interferon is in treatment of young patients with well 
compensated CLD who do not want long-term treatment or are planning family. 
Lamivudine: Advantages of Lamivudine are its lower cost, the many years of experience and 
its safety as it appears safe during pregnancy. The high rate of drug resistance is the main 
disadvantage of Lamivudine. 
Adefovir: Advantage of Adefovir is its activity against Lamivudine-resistant HBV and a 
lower rate of drug resistance compared to Lamivudine. 
Entecavir: Its potent antiviral activity is the main advantage along with a lower rate of drug 
resistance. Entecavir has a more important role in primary treatment of HBV than in patients 
 with Lamivudine resistant HBV. It has important role in patients with decompensated cirrhosis 
because of its potent antiviral activity and low rate of drug resistance. 
Tenofovir: Has more potent antiviral activity than Adefovir and is effective in suppressing 
wild-type as well as Lamivudine-resistant HBV. In treatment-naïve patients, Tenofovir may be 
used as first line treatment and in patients with Lamivudine, Telbivudine or Entecavir resistance. 
Immunosuppresion and Hepatitis B: 
Interplay between viral multiplication and the host's immune response determines the natural 
course of HBV infection. In patients with evidence of serological recovery, HBV persists in the 
body. Individuals who receive immunosuppressive therapy are at risk for HBV reactivation and a 
flare of their HBV disease. Reactivation can result in increased serum liver enzymes, hepatic 
failure, or death(161). Reactivation leads to an interruption of immunosuppressive therapy 
causing delay in the treatment of the underlying disease. 
 
Patients at risk of Hepatitis B activation: 
1) Chemotherapy: Patients receiving chemotherapy for hematological and solid 
malignancy(162)(163)(164). 
2) Autoimmune disease : Autoimmune diseases patients treated with immunosuppressive 
therapy are at risk of reactivation(6)                   
 3) Transplantation: Patients who have received stem cell or solid organ transplantation and 
on immunosuppresion are at risk for Hepatitis B reactivation. 
The risk depends on Immunosuppresion received and on HBsAG status. Individuals who are 
HBsAg-positive are at greater risk for HBV reactivation than those who are HBsAg-negative. 
HBsAg-positive individuals who are HBeAg positive  with  high HBV DNA  have highest 
risk(162)(163).  HBsAg-negative, anti-HBc-positive patients are also at risk for reactivation with 
immunosuppressive therapy. Reactivation can occur in anti-HBs-positive patients. Patients who 
have detectable anti-HBs have a lower risk of HBV reactivation, however titers can decrease to 
undetectable levels during immunosuppressive therapy. 
The immunosuppressive agent determines the risk for HBV reactivation. The number of drugs 
that are associated with reactivation are constantly increasing, such as glucocorticoids, traditional 
chemotherapeutic agents and biologic agents (anti-CD 20 agents, anti-TNF agents) and new 
classes of drugs such as mechanistic target of rapamycin (mTOR)-inhibitors and tyrosine kinase 
inhibitors 
 
Glucocorticoids :HBV reactivation occurs with high-dose and rapidly tapered regimens and 
moderate-dose, prolonged regimens. Reactivation has not been frequently described with low-
dose regimens (<20 mg or prednisone per day) even over prolonged periods(165). 
Glucocorticoids increases HBV replication. The enhanced viral replication is  because of 
glucocorticoids responsive element in the HBV genome that  increases  transcriptional 
activity(166). Serum aminotransferase tend to decrease inspite of the increase in viral replication. 
The reverse occurs once glucocorticoids are tapered, viral replication decreases and 
 aminotransferases increase(167)(168). It usually takes four to six weeks after withdrawal  to 
cause peak rise in aminotransferase (169). 
TNF alpha-inhibitors: HBV reactivation has also been associated with TNF alpha inhibitors 
among those with Crohn’s disease and psoriasis. Reactivation can occur in both who are HBsAg-
positive as well negative. Reactivation rates have been lower in HBsAg-negative individuals 
than those observed with rituximab (165). 
Anti-CD 20 agents : FDA has issued warnings for the monoclonal anti-CD20 antibodies 
atumumab and rituximab for an increased risk of  reactivation among patients positive for 
HBsAg or anti-HBc(170)(171)(172)(173). 
Stratifying risk of Hepatitis B activation: 
The AGA and the AASLD have categorized the level of risk for HBV reactivation based on type 
of immunosuppressant used and patients serological status(165). The level of risk determines 
whether or not preventive therapy is needed.  
 
Risk is stratified as follows 
Very high-risk: Those who are HBsAg-positive and are going to undergo 
hematopoietic stem cell transplantation and/or receive anti-CD20 therapy (eg, rituximab). 
Moderate-risk: Patients receiving cytotoxic chemotherapy without glucocorticoids 
and patients going to receive anti-TNF therapy or anti-rejection therapy for solid organ 
transplants are at moderate risk of reactivation in HBsAg positive individuals. Patients 
 who are HBsAg-negative and anti-HBc positive are at moderate risk for reactivation if 
they are going to undergo hematopoietic stem cell transplantation or going to receive 
anti-CD20 therapy (eg, rituximab or ofatumumab). 
Low-risk: HBsAg-positive patients receiving methotrexate or azathiporine are at low 
risk of reactivation. HBsAg-negative individuals are also at low risk if they are receiving 
cytokine inhibitors (eg, anti-CD52 agents) or high-dose glucocorticoids (eg, ≥20 mg/day) 
Very low-risk :  Patients receiving anti-TNF therapy, cytotoxic chemotherapy without 
glucocorticoids or anti-rejection therapy for solid organ transplants; HBV reactivation 
occurs rarely in HBsAg-negative patients. 
 
 
Clinical manifestation of reactivation of Hepatitis B: 
Reactivation is asymptomatic most of the times or some patients develop increase in HBV DNA 
levels or in transaminase levels. Some patients may also develop acute hepatitis, hepatic failure 
or hepatic decomposition   or death can also occur in some patients. Underlying cirrhotic patients 
have worse outcomes. 
Diagnosis: 
Diagnosis of reactivation is made when there is increase in HBV DNA level. 
HBV reactivation is diagnosed when with serological evidence of HBV patients have: 
1) A detectable HBV DNA level without previous evidence of virus.  
 2) A rise in HBV DNA of more than 2 log10IU/mL in patients who had HBV DNA present at 
baseline. HBV reactivation is defined as more than tenfold increase in HBV DNA compared 
with baseline in some studies(174). 
Treatment of HBV reactivation: 
Anti-virals should be administered to all who develop reactivation. Renal functions dictate the 
choice of anti-virals as Tenofovir is contraindicated in patients with renal dysfunction. The aim 
of the therapy is to prevent flare of disease and to avoid decompensation. Lamivudive has low 
barrier to resistance so Tenofovir and Entecavir is preferred. 
Treatment to prevent reactivation: 
In moderate to high risk patients, anti-viral therapy should be initiated. Antiviral therapy started 
after the onset of reactivation may not prevent a flare (175)(176)(177)(178).Monitoring should 
be done  in low risk patient and treated upon detection of flare. The choice of anti-virals is 
similar to as for treatment of flare. Type of immunosuppressive therapy, the degree of underlying 
liver disease and baseline HBV DNA level decides the period of therapy for treatment and 
prevention which is similar. Post Immunosuppresion treatment should be continued for at least 6 
months. Treatment should be continued for 12 months post Anti-CD 20 therapy as there is a lag 
in recovery in function of B cells. In patients who have undergone solid organ transplantation or 
hematopoietic stem cell, antiviral therapy may need to be continued long-term since they remain 
on long term immunosuppressive medications. In addition, certain HBsAg-positive patients (eg, 
those with a baseline HBV DNA >2000 IU/mL or evidence of cirrhosis) may need prolonged 
treatment. 
 Hepatitis B and inflammatory bowel disease.  
Inflammatory bowel disease (IBD) treatment is improved by the increasing use of 
immunosuppressors and use of biological. Immunomodulators are used more early and 
frequently in the course of disease as there is a substantial evidence for them. Many issues 
regarding relationship between Hepatitis B and IBD remained unresolved like prevalence of 
Hepatitis B and the target population in whom screening should be done(15). Natural history of 
Hepatitis B is clearly impacted by Immunosuppresion, however it is unclear which factors 
increases the reactivation of Hepatitis B on Immunosuppresion. It is also unclear regarding 
which patients need anti-viral prophylaxis and choice of anti-viral. There is a consensus for the 
use of Hepatitis B vaccination among inflammatory bowel disease however it is underused in 
practice.HBV vaccination efficacy in IBD patients and the factors modifying its efficacy are 
unknown(179). Modified vaccination scheduled can be used and is suggested to increase the 
efficacy rate in patients of inflammatory bowel disease. Anti-HBsAg titer testing is suggested 
after vaccination however the cut-off values for optimal response are controversial(180). Second 
course of vaccination is suggested after the first course fails however efficacy of the second 
course is not proven. 
 
Prevalence of Hepatitis B   in inflammatory bowel disease. 
Although not much information is available regarding the prevalence of hepatitis B in 
inflammatory bowel disease, these patients are at risk of reactivation of Hepatitis B specially 
those who are taking Immunosuppresion. Earlier studies showed significantly higher prevalence 
than the general population(181).This high prevalence was  due to surgical procedures and 
 blood transfusions  which suggest nosocomial infection. Other studies have reported HBV  
infection rates in IBD patients which are similar to the general population(182)(183). Newer 
studies showed no differences in prevalence of Hepatitis B between CD and UC. However, in 
some studies, the prevalence of HBV markers was higher in CD than in UC (167). 
 
Screening for Hepatitis B in inflammatory bowel disease 
All the patients should be screened at diagnosis of inflammatory bowel disease. Waiting should 
not be done for initiation of immunosuppressive therapy(184)(9)(185). 
Immunosuppresion effects on HBV infection: 
Reactivation manifestations can vary such as change in serum liver enzyme levels to fulminant 
hepatic failure and death after taking Immunosuppresion. Hepatitis B reactivation is a well 
known complication after chemotherapy.Multiple studies has shown reactivation of hepatitis B 
after Anti-TNF therapy(6)(186)(187)(188). 
Natural history of Hepatitis B in inflmamtory bowel disease: 
Development for cirrhosis in HBV-infected IBD patients is reported to be same as in general 
population with HBV infection. Immunosuppresion  in IBD, does not increase  the risk of 
progression to end-stage liver disease in contrast to HCV-infected patients who progress to liver 
cirrhosis and hepatocellular carcinoma after liver transplantation(189). 
 
 
 Anti-viral prophylaxis: 
 (EASL), (AASLD),and(ECCO) advise early introduction of nucleotide/nucleoside analogues for  
HBsAg-positive patients who will require immunosuppressive therapy(13) (190). In patients who 
are positive HBsAg titres with or without viral replication; anti-viral therapy should be 
administered. Prophylaxis is given irrespective of the type and number of immunosuppressants 
administered(184). In IBD patients,  it is recommended to start anti-viral prophylaxis 1–3  weeks 
prior to the initiation of immunosuppressive therapy and  to continue  therapy for six months 
after withdrawal(6)(190). 
Occult Hepatitis B: 
Is defined as persistence of B virus genome in HBsAg-negative individuals(191). Occult 
infection is common in patients who are positive for anti-HBc with or without anti-HBs. An 
AASLD guideline recommends screening for anti-HBc to detect occult HBV(184)(192). There  
are only few reports of HBV reactivation in an anti-HBc-positive/HBsAg-negative patient with 
CD treated with Immunosuppresion (193). Use of anti-viral prophylaxis in anti-HBc positive 
patients those who lack HBsAg cannot be recommended(194)(195). Prevalence of anti-HBc in 
voluntary blood donors is estimated to be 16% (196). 
Anti-viral prophylaxis: 
 In chronic HBsAg-positive carriers, anti-viral prophylaxis is recommended before initiating 
immunosuppressive agents.(13) According to  guidelines for HBV treatment; patients with high  
HBV DNA levels (>2000 IU/mL) should continue anti-viral therapy until endpoints like for any 
 other patient with hepatitis B are reached(197)(13). If immunosuppressive therapy is going to 
continue for more than one year, nucleotide/nucleoside analogues with a lower risk for 
generating drug-resistant mutations of HBV DNA should be preferred. 
Hepatitis B vaccination in inflammatory bowel disease: 
Vaccination prevents opportunistic infection IBD patients (8). In the course of IBD,  patients 
may need immunosuppressive therapy. Response rates to  vaccines, for example HBV vaccine 
seems to be lower in patients on immunosuppressive therapy (198). The time point of diagnosis 
of inflammatory bowel disease is the best time to vaccinate. Vaccine-related immunity duration 
appears to altered in patients with IBD  with or without Immunosuppresion; so modified dosing 
schedules or booster doses would be necessary(199).Routine testing for immunity is not 
recommended  after vaccination of adult, however testing is recommended for high-risk 
individuals such IBD patients(197)(179). An anti-HBs concentration of ≥10 mIU/mL measured 
one to three months after last dose of vaccination is considered a reliable marker of efficacy 
against infection according to the WHO (179)(200)(180).Those with anti-HBs concentrations 
<10 mIU/mL should be revaccinated with three additional doses(179)(201).There is a limited  
date available regarding the duration of immunological memory after Hepatitis B vaccination in 
immunocompromised patients. Immunocompromised patients should be tested annually to assess 
anti-HBs concentrations as in haemodialysis patients(202) as they are shown to have Hepatitis B 
infection after vaccination . Booster dose  can be administered when anti-HBs levels decreases to 
<10 mIU/mL(202). Testing anti-HBs concentrations annually and administering booster doses 
when anti-HBs levels decreases to <10 mIU/mL) should be considered for IBD patients on 
 immunosuppressive treatment however more studies are required to establish this 
recommendation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 METHDOLOGY: 
The study was designed as prospective case study analyzing the serological markers of Hepatitis 
B in patients with inflammatory bowel disease (IBD). It was presented to the Institutional 
Review Board & Ethics Committee, Christian Medical College, and Vellore and subsequently 
approved by the same. Patients with IBD were recruited between October 2013 and August 
2014. Informed consent was taken from the patients themselves or their guardians (in case of 
children). Relevant data were collected through direct interviews with patients or guardians (in 
case of children) in the outpatient clinic as well in the wards when admitted.  
 HBsAg, a Hepatitis B marker was sent for all the recruited patients and in addition Anti-
HBc was sent if HBsAg was found negative. Any patient found positive for serological markers 
of Hepatitis B was referred to department of Hepatology for further evaluation and management. 
Other investigations studied included Anti HCV & HIV status, liver function tests, imaging for 
evidence for chronic liver disease. Those positive for HBsAg were additionally tested for HBV 
DNA level and e Antigen status.  
 Demographic details, clinical, endoscopic and radiological details regarding 
inflammatory bowel diseases were entered into the proformas (Annexure 1). A detailed 
questionnaire was utilized to assess the risk factors for Hepatitis B transmission and vaccination 
status for hepatitis B. 
 
 
 
 Sample size: 
The sample size for this study was calculated to be 76 based on 20% prevalence of Anti HBc in 
the general population, confidence level of 0.95 and precision level of 9%. 
 
Statistical analysis: 
The results were analyzed using SPSS version 15. Mean, median, standard deviation (SD), range, 
and proportions were calculated as appropriate. Categorical variables were analyzed using the 
Chi-square test with Yates’ correction as applicable while continuous data was analyzed using 
Mann–Whitney U test. A ‘p’ value less than 0.05 was considered statistically significant. 
 
 
 
 
 
 
 
 
 
 
 Participants: 
Inclusion criteria: All the patients with diagnosis of inflammatory bowel disease which 
included  
1) Ulcerative colitis 
2) Crohn’s disease 
3) Indeterminate colitis 
Exclusion criteria: Patients (or parents/guardians in case of minors or incompetent patients) 
unwilling to give informed consent. 
 
Definitions: 
Ulcerative colitis: Chronic inflammatory condition causing mucosal inflammation in 
continuous segments of the colon without granulomas on biopsy, involving the rectum and a 
variable extent of the colon and characterized by a relapsing and remitting course. 
Crohn’s disease: Chronic inflammatory disorder involving any part of the alimentary tract 
from mouth to anus but with a propensity for the distal small intestine and proximal large bowel, 
inflammation being discontinuous along the longitudinal axis of the intestine with possible 
involvement of all layers of the gut wall from mucosa to serosa. 
 Indeterminate colitis:  Chronic inflammatory bowel disease where biopsies show no 
equivocal features to suggest ulcerative colitis or crohn’s disease are labeled as indeterminate 
colitis or colitis unspecified. 
 
Serological markers of hepatitis B: 
Hepatitis B surface antigen (HBsAg): Hallmark of HBV infection, usually detected by 
radioimmunoassay (RIA) or enzyme immunoassays (EIA). 
Anti-HBc: It can be detected in three situations: 
1) Window period of acute hepatitis B where the anti-HBc is mainly IgM class 
2) After recovery from acute hepatitis B when anti-HBs decrease to the extent that it cannot be 
detected. 
3) After many years of chronic HBV infection when HBsAg titer decreases below the cutoff for 
detection.  
Present and past HBV infection was defined according to the terminology adopted by the 
National Institutes of Health conferences on Management of Hepatitis B (197). Present HBV 
infection included chronic hepatitis B and inactive HBsAg carrier state and past HBV infection 
included resolved hepatitis B (presence of anti-HBc with or without anti-HBs). 
 
 
Variables: 
Broad groups of variables included 
1. Basic demographic details 
 2. IBD related history 
3. Risk factors for hepatitis B transmission 
4. Other clinical details 
5. Investigations 
6. Hepatitis B immunization details 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Results: 
A total 76 patients with inflammatory bowel disease were recruited for the study. Of the 76 
patients, 42(55.3%) patients had diagnosis of ulcerative colitis, 33(43.4%) patients had diagnosis 
of Crohn’s disease while only one patient had indeterminate colitis. The overall mean age for the 
entire study population was 37.5±13.9 years. Majority of the patients were from the following 
states: West Bengal: 25(32.9%); Tamil Nadu:16(21.2%); Jharkhand:13(17.1%); Andhra 
Pradesh:8(10.5%).  The overall male: female ratio was 1.7:1 (48:28). 44(58%) of the patients 
were from an urban background. The overall median total duration of illness at the time of 
inclusion of the study was 35(1-410) months while the overall median duration prior to diagnosis 
of illness was 7.5(1-228) months. Table 1 depicts the baseline characteristics of the study 
patients with IBD. 
 
 
 
 
 
 
 
 
 Figure No.1: Diagnosis in inflmamtory bowel disease patients 
 
 
 
 
 
 
 
 
 Figure.2: Sex distribution of Ulcerative colitis patients 
 
Figure.3:Sex wise distribution of Crohn’s disease patients 
 
  
Figure.4:  State wise distribution of cases 
 
 
 
 
 
 
 Figure.5: Regional distribution of cases 
 
Figure.6:Demographic distribution of cases 
 
  
Disease characteristics and related factors: 
The mean ages of diagnosis for those with ulcerative colitis and Crohn’s disease were 39.8±12.9 
years and 34.3±14.7 years respectively. The Montreal classification was utilized to 
phenotypically classify patients with ulcerative colitis and Crohn’s disease. Among patients with 
ulcerative colitis, 7 (16.7%), 15(35.7%) and 20(47.6%) patients had proctitis, left sided colitis 
and pancolitis respectively.  
Among those with Crohn’s disease; 7(21.2%), 20(60.6%) and 6(18.2%) patients were 
below 16, between 16 and 40 and more than 40 years respectively. 10(30.30%), 4(12.12%), 
19(57.57%) and 0 (0%) had ileal, ileocolonic, colonic and upper gastrointestinal involvement. 
The nature of Crohn’s disease was non-stricturing & non-penetrating, stricturing and fistulising 
in 14(42.4%), 14(42.4%) and 5(15.2%) respectively.  
History of IBD related surgery was present in 2(4.8%) patients with ulcerative colitis and 
8(24.2%) patients with Crohn’s disease. In those with ulcerative colitis, both patients had history 
of surgery for anal fistula while in those with Crohn’s, 3(9.1%) had small bowel resection, 
3(9.1%) had right hemicolectomy while 2(6.1%) had surgery for anal fistula. 
Although use of most medications like mesalamine, azathiporine, methotrexate and 
antibiotics were almost similar in both ulcerative colitis and Crohn’s patients, the former (66.7%) 
had significantly more steroid intake than the latter (30.3%).  
 
 
  
 
Figure.7: Medical therapy in patients of inflammatory bowel disease. 
 
 
 
 Figure.8: Montreal classification of Ulcerative colitis 
 
Figure.9:Montreal classfication of Crohn’s disease according to age 
 
 Figure.10: Montreal classification of Crohn’s disease according to location 
 
Figure.11:Montreal classfication of Crohn’s disease according to behavior. 
 
 
 Table1: Baseline characteristic of study patients with IBD 
 Ulcerative colitis 
(n=42) 
Crohn’s disease 
(n=33) 
Indeterminate 
colitis (n=1) 
P 
value 
Mean age of 
diagnosis(SD)in years 
39.8(12.9) 34.3(14.7) 48 0.092 
Median total duration 
at inclusion (range) in 
months 
27.5 (1-410) 36(2-328) 7 0.341 
Duration prior to 
diagnosis(range) in 
months 
6(1-80) 20(2-228) 5 0.004* 
Male: Female 26(61.9%)/16(38.1%) 22(66.7%)/11(33.3
%) 
0/1 0.809 
Habitat: Urban /Rural 21(50.0%)/21(50.0%) 22(66.7%)/11(33.3
%) 
1/0 0.166 
Surgery related to 
IBD: 
Resection: 
Right 
hemicolectomy 
 
0(0%) 
0(0%) 
 
1(3%) 
3(9.1%) 
 
0 
0 
 
 Medications : 
Mesalamine 
Steroids 
Azathioprine 
Methotrexate 
Antibiotics 
 
42(100%) 
28(66.7%) 
18(42.9%) 
0(0%) 
7(16.7%) 
 
32(97%) 
10(30.3%) 
13(39.4%) 
2(6.1%) 
7(21.2%) 
 
1 
1 
0 
1 
0 
 
0.44 
0.002* 
0.816 
0.19 
0.767 
Montreal 
classification: 
Extension 
E1:   7(16.7%) 
E2: 15(35.7%) 
E3: 20(47.6%) 
Age at diagnosis 
A1:   7(21.2%) 
A2: 20(60.6%) 
A3:   6(18.2%) 
 
Location 
L1: 10(30.30%) 
L2: 4(12.12%) 
L3: 19(57.57%) 
L4: 0 (0%) 
 
Behavior 
B1: 14(42.42%) 
B2: 14(42.42%) 
B3: 5 (15.15%) 
  
 
 
 Prevalence of Hepatitis B markers in patients of inflammatory bowel disease 
Hepatitis B markers (HBsAg/Anti-HBc) were positive in 9(11.8%, 95% CI: 6.4-21%) out of 76 
patients with inflammatory bowel disease. None of the patients who were positive for hepatitis B 
markers had features of chronic liver disease or portal hypertension. Two patients who were 
positive for HBsAg were on anti-virals. Both the patients had low or negative viral levels. We 
had also tested for presence of hepatitis C virus which turned out to be negative for all the 
samples. Table 2 depicts the frequencies of hepatitis B markers in the study population. 
 
Table 2: Prevalence of Hepatitis B markers in the study population 
 Ulcerative 
colitis 
(N=42) 
Crohn’s disease 
(N=33) 
Indeterminate colitis 
(N=1) 
HBsAg +ve 1/42(2.4%) 1/33(3%) 0(0%) 
Anti HBc +ve 5/41(12.2%) 2/32(6.3%) 0(0%) 
HCV 0 0 0 
 
 
 
 
 
 Figure.12: Prevalence of Hepatitis B serological markers in cases 
 
 
 
 
 Factors related active or past Hepatitis B infection 
Multiple risk factors were studied for active or past hepatitis B infection and compared between 
those who were positive and negative for hepatitis B related viral markers (Table 3). Out of the 
multiple risk factors studied mean age (P=0.034), non IBD related surgeries (P=0.009) and non 
IBD related hospital admission (P=0.008) were significantly more common in those positive for 
viral markers compared who were not.  
Table 3: Risk factors related to active or past hepatitis B infection 
 Negative 
viral markers 
(n=67) 
Positive 
viral markers 
(n=9) 
P value 
Mean age(SD) 36.3(13.9) 46.7(10.2) 0.034* 
Male gender 43(64.2%) 5(55.6%) 0.718 
Alcohol 4(6%) 2(22.2%) 0.146 
Habitat (Urban) 36(53.7%) 8(88.9%) 0.071 
Parenteral drug abuse 0(0%) 1(11.1%) 0.118 
Parenteral injections 66(98.5%) 9(100%) 1 
Dental 14(20.9%) 0(0%) 0.197 
Family history 0 0 - 
Maternal history 0 0 - 
Surgeries (IBD) 10(14.9) 0 0.597 
Surgeries (Non-IBD) 9(13.4%) 5(55.6%) 0.009* 
 Transfusions 14(20.9%) 2(22.2%) 1 
Previous invasive 
procedures 
56(83.6%) 6(66.7%) 0.354 
High risk sex 1(1.5%) 0 1 
Admission (IBD 
related) 
28(41.8%) 4(44.4%) 1 
Admission (non- IBD 
related) 
14(20.9%) 6(66.7%) 0.008* 
Hepatitis B in partner 0 0  
Steroids 35(52.2%) 4(44.4%) 0.733 
Azathioprine 30(44.8%) 1(11.1%) 0.074 
Methotrexate 3(4.5%) 0(0%) 1 
Sharing towels 3(4.5%) 2(22.2%) 0.104 
Health care worker 2(3%) 0 1 
Tattooing 1(1.5%) 0 1 
Piercing 21(31.3%) 4(44.4%) 0.465 
 
 
 
 
 
  
Hepatitis B vaccination status 
Out of 76 patients studied, only 7(9.2%) patients had completed 3 doses of vaccination. Out of 
these 7 patients, 6 were negative for hepatitis B markers while one patient tested positive for 
Anti-HBc. 
 
      Figure.13: Vaccination status of cases 
 
 
 
 
 Discussion: 
Most available studies in published literature on the prevalence of hepatitis B serological 
markers in inflammatory bowel disease are from Western countries. (183)(182)(109)(203) 
Although there are three studies from East Asia , there are none from the Indian subcontinent 
(204)(205)(206). Prevalence rates of chronic hepatitis B in the general population varies across 
regions across the world with India falling under the intermediate prevalence 
category(207)(208). This study is the first one from India reporting the prevalence of hepatitis B 
infection among our patients with inflammatory bowel disease.  Besides this is the first Indian 
study to provide hepatitis B vaccination rate in this vulnerable population. 
Compared to other studies, we had only 76 patients with IBD, of which 55.3% had 
ulcerative colitis while 43.4% had Crohn’s disease. There was one patient with indeterminate 
colitis. The largest series of this kind was the Spanish multicentre study by Loras el at in which 
they had 2076 patients (44.7% with ulcerative colitis and 54.3% with Crohn’s) over 1 year. 
Chevaux et al from France recruited 315 patients (20% ulcerative colitis and 80% Crohn’s) over 
a 4 year period. Katsanos et al from Greece reported a single centre study on 482 patients (64% 
ulcerative colitis, 30% Crohn’s & 6% indeterminate colitis). From the United States, Ben Musa 
et al had 500 patients (ulcerative colitis 41.2%, Crohn’s 58.4%, indeterminate colitis 0.4%) in 
their 3 year single centre retrospective series.  There were 176 patients (42% ulcerative colitis 
and 58% Crohn’s disease) in the single centre, two year, prospective Brazilian series reported by 
Tolentino et al.  The largest Asian series was a 12 year, single centre retrospective series from 
China conducted by Huang et al in which they had 714 patients (44.4% ulcerative colitis, 55.6% 
Crohn’s). Kim et al from Korea recruited 513 patients (53% ulcerative colitis and 47% Crohn’s) 
 in their prospective, 3 year multicentre study. Leung et al had 267 patients (62.2% ulcerative 
colitis and 37.8% Crohn’s) in their centre located at Hong Kong. Like most series, ours was a 
single centre study carried out over a year. The funds available for the study provided by the 
institutional fluid grant were taken into consideration while calculating our sample size We had 
more number of ulcerative colitis than Crohn’s in our study similar to the pattern reported in our 
country’s national survey of inflammatory bowel disease(209). 
It is recommended that all IBD patients be screened for hepatitis B markers to rule the 
presence of hepatitis B infection and the optimal time for screening would be at the time of 
diagnosis(190). 
In our study, male patients (66.7%) outnumbered their female counterparts (33.3%). The 
male: female ratio favoured  the former even in the Indian survey (1.4 in ulcerative colitis and 
1.3 in Crohn’s(209). Male predominance was also seen in most studies(206)(204)(205)(210) 
However, the series from US, Brazil and Italy had more female patients(211)(109)(203) . In the 
series from Loras et al from Spain, male: female ratio was nearly one(173). Chevaux et al 
reported a male: female ratio of 0.38 among those with Crohn’s disease and 0.62 among those 
with ulcerative colitis (174).  
Majority of our patients were from urban areas. This was possibly due to their better 
accessibility to tertiary level healthcare compared to rural patients. The referral pattern to our 
centre may explain the predominance of patients from eastern and southern India. The study by 
Ben Musa et al (Chicago, USA) was the only one in which there was mention about race and 
ethnicity. Majority of the patients were Caucasian while Hispanics formed 8% of those with 
ulcerative colitis and 4.8% of those with Crohn’s(203).  
   The overall mean age of the patients in our study was 37.5±13.9 years. The mean age for 
ulcerative colitis patients was 39.8±12.9 years while it was 34.3±14.7 years for Crohn’s patients. 
In the Indian survey of IBD, mean age of patients with ulcerative colitis and Crohn’s  were 38.5 
(13.5) and 35.9 (13.9) years respectively(209). Most Western studies had older patients in their 
series(203)(182)(210)(109). However, Chevaux et al had younger patients in their study 
population where median (IQR) age was 33(24-43) years(183) .With regard to Asian studies; 
Huang et al from China had their overall mean age (37.25 +/- 9.83 years) similar to ours.  Kim et 
al from Korea reported mean age of 29.89+/- 11.72 years from Crohn’s and 43.97+/- 15.31 for 
their ulcerative colitis patients while Leung et al from Hong Kong reported figures of 42.2+/- 14 
and 51.7+/-14.1 years respectively(204).  
 The overall median duration of illness at the time of inclusion in our study was 35(1-410) 
months; 27.5(1-410) months for ulcerative colitis and 36(2-328) months for Crohn’s.  The mean 
duration of illness was much longer in the series from Spain (100 months), US (134+/-127.6 
months) and Italy (9.9 +/- 7.7 years)(182)(203)(109) . 
 Use of immunosuppressive drugs can exacerbate hepatitis B infection in those with IBD. 
Steroids, azathiporine and methotrexate was used in 38(50%), 31(40.8%), 2(2.6%) in our study 
population respectively. The steroid use was more significantly (p=0.002) seen in those with 
ulcerative colitis (66.7%) than Crohn’s disease (30.3%). None of our patients had a history of 
biologic agents use in the treatment of IBD. Immunosuppressive and biologic agents were widely 
used in other studies. In the study by Tolentino et al 4% used immunosuppressant drugs, 42% 
used steroids and both the drugs were used in 26% patients(211). In the study by Chevaux et al, 
overall 68.9% (95% CI: 63–74) were treated with immunosuppressive agents including Anti 
TNFα agents. Azathioprine, methotrexate and Anti-TNFα agent use was seen in 52%, 4.8% and 
 52.4% patients with Crohn’s and 31.7%, 15.9% and 27%, patients with ulcerative colitis 
respectively(183). Loras et al reported 79% of their patients were treated with 
immunosuppressive therapy while Ben Musa et al reported a figure of 60%(182)(203). The 
largest series for China by Huang et al reported that 23% had immunosuppressive therapy while 
8.5% received Infliximab. Kim et al from Korea reported that steroids, thiopurines and biological 
were used in 49.8%, 53.1%, 13.7% of Crohn’s and 46%, 23.2 %, 2.6% of ulcerative colitis 
patients respectively(204).  In study by Leung et al from Hong Kong; steroids, thiopurines and 
biological were used in 22.8%, 49.5%, 14.95% of Crohn’s and 13.9%, 10.8%, 1% of ulcerative 
colitis patients respectively(205).  Steroids and immunosuppressant can cause reactivation of 
latent hepatitis B virus. Unlike cancer patients who are frequently exposed to cytotoxic 
chemotherapy and immunomodulators, there is a lack of awareness even among 
gastroenterologists that IBD patients are also vulnerable to reactivation of hepatitis B virus since 
they are also exposed to similar treatments(7).  
There are several reports of reactivation of hepatitis B virus in IBD patients when exposed to 
steroids, thiopurines, anti TNF drugs. There is also increased level of reactivation in patients  
when administered a combination of these drugs(10).  
 There is increased risk of death due to fulminant liver failure after administration of 
chemotherapy in 4 to 60% cases. In patients with IBD who are HBs Ag positive, it would be 
important to cover them with antivirals during their course of steroids, immunomodulators and 
biologic agents. Tenofovir and Entecavir are preferred to lamivudine for antiviral 
prophylaxis(10) The strategy for management of HBs Ag-ve but Anti HBc +ve patients is a 
matter of debate. The ECCO guideline recommends that routine antiviral prophylaxis is not 
recommended. However it advises to monitor LFT, HBV serology and viral loads. NIH (2009) 
 consensus advocates anti-viral prophylaxis for those patients planned for organ or bone marrow 
transplantation or if aggressive or prolonged chemotherapy is considered. 
In our study13.2% patients had IBD related surgery while 18.5% had non- IBD related 
surgery. Loras et al from Spain reported 28% of their patients had IBD related surgery while 
Chevaux et al from France reported a figure of 33.7% (95% CI: 28–39). In the latter series; 21%, 
11.5% & 14.3% of Crohn’s patients underwent ileal resection, colectomy and perianal surgery 
while 7.94% patients underwent colectomy for ulcerative colitis(183)(182). From Hong Kong 
study, Leung et al reported that 33.7% and 18% patients of Crohn’s and ulcerative colitis 
respectively had previous history of bowel resection(205). Huang et al from China had 22% who 
underwent IBD related surgery while Kim et al (Korea) reported a figure of 
17.3%(204)(206).Papa et al from Italy reported that 53.2% had previous history of surgery(109). 
The highest figure for past history of surgery was 66.5% reported by Tolentino et al from 
Brazil(211).  Compared to other series, history for IBD related surgery was least in our study 
group. Like Tolentino et al, we had more non-IBD related surgery than IBD related surgery. 
Other than the Brazilian and Chinese series; most series did not provide data on non-IBD related 
surgeries. 
According to Montreal classification in ulcerative colitis pancolitis (47.6%) was the 
commonest presentation in our study. In those with Crohn’s disease, commonest age group was 
A2 i.e., between 17-40 years (60.6%); ileocolonic(57.6%) was the commonest location while 
B1(inflammatory) and B2(stricturing) were most common type of  disease behavior, both being 
42.4%.These results were similar to that reported by Loras et al where pancolitis (41.7%) was the 
commonest presentation in ulcerative colitis while A2(68.6%), ileocolonic location(41.3%) and 
B1 (46.5%) were the commonest presentation seen in Crohn’s(182). In contrast in  the study by 
 Chevaux et al; B3 i.e. penetrating (41.7%) was the commonest behavior in Crohn’s disease(183). 
The Asian studies had similar clinical presentations to ours with respect to both Crohn’s and 
Ulcerative colitis except that  isolated proctitis was the most common extent of UC in the series 
from China and Korea(206)(204).  
In our study, the overall prevalence for serological markers of hepatitis B infection was 
11.8%; HBs Ag was present in 2.6% while anti HBc was seen in 9.5% of those tested. More 
patients with ulcerative colitis (12.2%) were anti HBc positive compared to those with Crohn’s 
(6.3%) although not significantly.  The prevalence of hepatitis B markers (11.8%) was not 
significantly different from the available figure in the general population (20.3%) (212). 
On comparison with other studies, Katsanos et al from Greece & Chevaux et al from 
France reported the least (2.3% & 2.54% respectively) figures for seroprevalence of hepatitis B 
markers. This was closely followed by Ben Musa et al from US (3.6%). The highest prevalence 
rates were reported from China (Huang et al, 40.62%) followed by Korea (Kim et al, 30%). From 
Brazil, Tolentino et al reported seroprevalence of 17%(206)(204).  
The highest overall prevalence of HBsAg among IBD patients were from all from Asian 
studies: Leung et al (6.7%), Huang et al (5.46%) & Kim et al (3.7%). The highest overall 
prevalence of anti HBc among IBD patients were again from Asia: Huang et al(40.62%), Kim et 
al (30%) & Leung et al(28.5%)(206)(204)(205). 
.Except for the studies from US (Ben Musa et al) and France (Chevaux et al), the 
prevalence of anti HBc in ulcerative colitis exceeded the prevalence seen in Crohn’s 
disease(203)(183). 
 The variations in seroprevalence of hepatitis B in IBD patients across the above 
mentioned could be possibility explained by the differences in the local prevalence of hepatitis 
B, regional differences in the same country, vaccination policies & implementation and the age 
of the study subjects(183). Understandably, higher figures of seroprevalence were obtained in 
studies reported from Southeast Asia and Brazil while the lowest were reported from Europe. 
Italian data showed that even in the same country; adoption of important public health measures 
like improved screening of blood and blood products, universal precautions in health care 
settings and effective implementation of hepatitis B vaccination programs could result in reduced 
rates of seroprevalence over a period of time(109). Our data from India would suggest that our 
country stands somewhere in the middle not only in terms of prevalence but also with regard to 
successful implantation of crucial public health measures.  
On analyzing the risk factors associated with hepatitis B infection in IBD patients, older 
age was commonly noted in the available studies including ours(182)(211)(206). The other 
significant risk factors obtained in the study from Spain were family history of hepatitis B 
infection and presence of moderate-severe IBD(182). In the study from China from Huang et al, 
family history of hepatitis B and IBD related admissions were the other significant risk 
factors(206). In our study, history of non-IBD admissions and non-IBD surgeries were noted to 
be significantly associated with risk for hepatitis B infection.  
An older age is associated with longer disease duration of IBD which increases the risk of 
contracting hepatitis B infection(211) Family history of hepatitis B infection indicates the 
increased risk for viral transmission among household contacts (eg: sharing of razors & 
toothbrushes) and also through sexual contact. Vertical transmission from infected mother to 
fetus is an important route of transfer in developing countries. Moderate – severe IBD may lead 
 to increasing need for IBD related admissions,  parenteral  injections and surgeries. Interestingly 
in our study, the significant association between non-IBD related admissions/surgeries and 
hepatitis B infection could indicate that these are opportunities for transmission of the virus. 
Improper sterilization and reuse of sharp instruments, frequent and unwarranted parenteral 
injections, substandard blood banking facilities and lack of awareness of infection control in 
primary and secondary health care settings in India may contribute to increased risk for 
infection(213)(214). 
Effective vaccination is generally defined as presence of anti HBs titres > 10 IU/ml 
without anti HBc positive(183). In the Spanish study, effective vaccination was seen in 12% of 
the patients; 12.9% in Crohn’s and 11.1 % in ulcerative colitis. This study also noted that 
younger IBD patients were more significantly protected against hepatitis B infection compared to 
their older counterparts (56.5%vs 12.3%) suggesting that vaccine effectiveness decreases with 
age(182). The highest rate for effective vaccination was reported from France by Chevaux et al 
to be 48.9% (Crohn’s 45.6% and ulcerative colitis 61.9%)(183). Papa et al from Greece reported 
a vaccination rate of 23.9%(109). From Asia; Kim et al from Korea reported effective 
vaccination of 38.1% (Crohn’s 37.2% and ulcerative colitis 38.9%) while Leung et al reported a 
rate of 26.6% (Crohn’s 24.7% and ulcerative colitis 27.7%)(204)(205). Huang et al from China 
reported an effective vaccination rate of 21.57%(206).  Out of a total of 193 patients, Ben Musa 
et al in their retrospective series reported that  (49%) were vaccinated(203).  In our study, only 
9.2% ever received 3 doses of hepatitis B vaccine. We did not check the anti HBs titres in these 
patients as part of the study.  
Although the ECCO guidelines recommend hepatitis B vaccination in inflammatory 
bowel disease patients, it is underutilized(15). Unfortunately the awareness about the need for 
 hepatitis B vaccination particularly among physicians is low. In countries where universality of 
hepatitis vaccination is ensured, lower rates of hepatitis B seromarker prevalence were noted. 
The highest effective vaccination obtained in the French study maybe attributed to the country’s 
vigorous vaccination program. Coverage of high risk groups for hepatitis B infection was started 
in 1981. By 1995, hepatitis B vaccine became part of the French national immunization 
schedule(183).  
It is recommended that hepatitis B vaccination be administered at the time of diagnosis of 
IBD prior to the start of immunosuppressant (10) 
Several factors have been identified for the poor or non response to hepatitis B 
vaccination in healthy subjects like immunosuppressive disease, older age, male sex, smoking 
and increased body mass index(10).Efficacy of vaccine in IBD patients may decrease with age 
shown in the Spanish study. Use of immunomodulators may also decrease vaccine effectiveness. 
Chaparro et al also noticed that patients on TNF agents had poor response rates(10). It is also felt 
that Crohn’s per se could affect vaccine effectiveness by modulating Th1/Th2 balance which in 
turn may dysregulate cytokine production leading to diminished vaccine response(183). Not only 
should the full course of hepatitis B vaccination be given, it should be ensured that adequate 
titres are obtained.  Those who have inadequate response may need a second course of hepatitis 
B vaccination. Despite initial failure, it is felt that 50% of those who take a second course may 
develop adequate antibody response to the vaccine(184). 
 
 
 
 Limitations of the study: 
1) Single centre study 
2) Being a major tertiary care centre in South India, a referral bias is expected in our study. 
3) Smaller sample size 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Conclusions: 
1) The prevalence of serological markers of hepatitis B exposure in our study patients with 
inflammatory bowel disease patients was 11.8%. 
2) An older age, history of non-IBD related admission and non-IBD related surgery were 
significantly associated with risk for hepatitis B infection. 
3) Hepatitis B vaccination rate among our study population was very low (9.2%) indicating that 
it was grossly underutilized. 
4) There is a need to create awareness among physicians regarding the need for hepatitis B 
vaccination in patients with inflammatory bowel disease. 
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 Proforma: 
Serial No:                                                                                             Date: 
PROFORMA (HEP B & IBD) 
NAME:                                                                                                          HOSPITAL NO: 
AGE:                                                                                                             SEX:     1. MALE      2. FEMALE 
OCCUPATION: 
POSTAL ADDRESS: 
 
HABITAT:         1) URBAN      2) RURAL                                
PHONE NO:     1)                                                                 2) 
EMAIL: 
IBD RELATED HISTORY 
DIAGNOSIS: 1) CROHN’S DISEASE   2) ULCERATIVE COLITIS 3) INDETERMINATE COLITIS 
MONTH AND YEAR IN WHICH FIRST DIAGNOSIS WAS MADE: 
DURATION   OF ILLNESS PRIOR TO FIRST DIAGNOSIS (MONTHS): 
TOTAL DURATION (MONTHS): 
SITE OF INVOLVEMENT: 
 CROHN’S:   1) ILEAL (1.YES 2.NO)    2) COLONIC (1.YES 2.NO)       3) ILEOCOLONIC (1.YES 2.NO)             
                     4) UPPER GI DISEASE (1.YES 2.NO)    5) PERIANAL (1.YES 2.NO)     
 UC:              1) PROCTITIS (1.YES 2.NO)   2) LEFT SIDED (1.YES 2.NO)     3) PANCOLITIS (1.YES 2.NO)     
EXTRAINTESTINAL MANIFESTATIONS: 
    JOINT DISEASE - 1) AXIAL   2) PERIPHERAL   3) NOT INVOLVED 
ORAL DISEASE-    1) YES   2) NO               If YES, mention: 
SKIN DISEASE-    1) YES   2) NO               If YES, mention: 
EYE DISEASE -     1) YES   2) NO              If YES, mention: 
    LIVER DISEASE - 1) YES   2) NO               If YES, mention: 
BEHAVIOUR OF CD: 
    1. NON STRICTURING, NON FISTULISING  
    2. STRICTURING                                             
    3. FISTULISING                                              Type:         
COLORECTAL MALIGNANCY:                        1) YES   2) NO                     
CURRENT DRUGS:  
      AMINOSALICYLIC ACID   1) YES   2) NO                    
      STEROIDS                          1) YES   2)                        ORAL / INTRAVENOUS 
      AZATHIOPRINE                1) YES   2) NO                   
       METHOTREXATE              1) YES   2) NO                            
      INFLIXIMAB                       1) YES   2) NO                        
      CYCLOSPORINE                  1) YES   2) NO                   ORAL / INTRAVENOUS  
      ANTIBIOTICS                      1) YES   2) NO                   ORAL / INTRAVENOUS 
                            TYPE: 
PAST HISTORY OF DRUGS:  
      AMINOSALICYLIC ACID    1) YES   2) NO                    DURATION (M) 
      STEROIDS                            1) YES   2) NO                    ORAL / INTRAVENOUS        NO. OF COURSES USED: 
      AZATHIOPRINE                1) YES   2) NO                    DURATION (M) 
      METHOTREXATE             1) YES   2) NO                    DURATION (M)            
      INFLIXIMAB                      1) YES   2) NO                    DURATION (M)                      
      CYCLOSPORINE                   1) YES   2) NO                    DURATION (M)                      ORAL / INTRAVENOUS  
      ANTIBIOTICS                       1) YES   2) NO                    DURATION (M)                      ORAL / INTRAVENOUS 
      TYPE: 
SURGERY:                                1) YES   2) NO                   IF YES, TYPE OF SURGERY    ____________________ 
HISTORY OF ALTERNATIVE MEDICINE   1) YES  2) NO    
1) AYURVEDIC 2) HOMEOPATHY 3) UNANI  4) OTHERS (MENTION) 
 
 RISK FACTORS FOR HBV TRANSMISSION 
HISTORY OF PARENTERAL INJECTIONS:       1) YES     2) NO    
PARENTERAL DRUG ABUSE:                          1) YES     2) NO 
HISTORY OF TRANSFUSIONS:                        1) YES      2) NO           PRODUCT USED & NO: 
MATERNAL HISTORY OF HEPATITIS B:           1) YES     2) NO 
DENTAL   PROCEDURES:                                   1) YES     2) NO 
BODY TATOOING:                                             1) YES   2) NO 
HISTORY OF PIERCINGS:                                   1) YES   2) NO 
SHARING OF BRUSHES/RAZORS/EARRINGS:   1) YES   2) NO   ITEM: 
SHARING OF TOWELS:                                        1) YES   2) NO 
WHETHER PATIENT IS HEALTH CARE WORKER?   1) YES   2) NO 
FAMILY HISTORY OF HEPATITIS B:                         1) YES   2) NO 
HISTORY OF HEPATITIS B IN PARTNER:                  1) YES   2) NO 
PREVIOUS IBD RELATED ADMISSIONS:                  1) YES   2) NO 
PREVIOUS NON-IBD RELATED ADMISSIONS:         1) YES   2) NO 
 
 
 HISTORY OF OTHER INVASIVE PROCEDURES (LIKE INTERVENTIONAL RADIOLOGY, INTUBATIONS, 
ENDOSCOPIES, TAPS, PUNCTURES, BIOPSIES):    1) YES   2) NO 
               DETAILS: 
SURGERY UNRELATED TO IBD:                                 1) YES   2) NO 
               DETAILS: 
HIGH RISK SEXUAL BEHAVIOUR                               1) YES   2) NO 
OTHER CLINICAL DETAILS: 
ALCOHOL CONSUMPTION:                                       1) CURRENT   2) FORMER   3) NEVER  
              QUANTITY:       UNITS/WEEK:                YEARS: 
HISTORY OF LIVER DISEASE- JAUNDICE/CLD/ DECOMPENSATION: 1) YES   2) NO 
              DETAILS: 
PAST HISTORY OF DOCUMENTED HBV FLARE:           1) YES   2) NO 
HISTORY OF ANTIVIRALS:                                            1) YES   2) NO      
 
 
 
 
 
 INVESTIGATIONS: 
HBsAg:                                1) POSITIVE   2) NEGATIVE      Anti HCV:                          1) POSITIVE   2) NEGATIVE       
HIV:                                      1) POSITIVE   2) NEGATIVE      Anti HBc (Total):             1) POSITIVE   2) NEGATIVE       
HBeAg:                              1) POSITIVE   2) NEGATIVE      Anti-HBe:                   1) POSITIVE   2) NEGATIVE       
HBV DNA:        1) POSITIVE   2) NEGATIVE       HBV viral load:     
LFT (Total Bb/ Direct Bb / Prot /Alb / SGOT / SGPT / ALP):  
INR: 
ABD IMAGING  
USG   1) YES 2)NO 
CT 1) YES 2)NO 
MRI 1) YES 2)NO 
IMAGING FINDINGS: 
CLD 1) YES   2) NO                   PHT 1) YES   2) NO                   HCC 1) YES   2) NO     
HEPATITIS B IMMUNIZATION DETAILS 
PRIOR HBV VACCINATION: 1)YES  2)NO 3)UNSURE  
HOW MANY DOSES: 1/2/3 
DURATION SINCE 3RD DOSE (M): 
WHETHER EVER Anti-HBs CHECKED:   1) YES   2) NO   
 WHETHER Anti-HBs titer > 10 mIU/ml:  1) YES   2) NO          
COUNSELLING   : ADVISED   IMMUNISATION   1) YES   2) NO  
THREE DOSES RECEIVED   1) YES   2) NO 
           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
